Andrew Ko
Professor · University of California (San Francisco) School of Medicine
Credentials: · · ·
History
1999–2001
- 1991–1995
1987–1991- 1988–1991
Research
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Nature Medicine · 2011 · 1,517 citations
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
New England Journal of Medicine · 2021 · 1,511 citations
JAMA Oncology · 2018 · 1,507 citations
42 papers
22 papers
16 papers
- EO
15 papers
15 papers · 2 as a fellow
- WK
13 papers
12 papers · 2 as a fellow
12 papers
Grants
- 2011–2014
Dual Targeting of MEK and EGFR Signaling Pathways in Advanced Pancreatic Cancer
National Cancer Institute · R21
Contact PI · $604.3K · University of California, San Francisco
National Cancer Institute · P30
Project lead · $603.8K · University of California, San Francisco
Clinical trials
- 2022–2026
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
CG Pharmaceuticals, Inc
- 2017–2021
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Principal investigator · Terminated · Phase 1
AbGenomics B.V Taiwan Branch
- 2015–2018
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
Principal investigator · Terminated · Phase 2
Andrew Ko
- 2015–2017
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Principal investigator · Terminated · Phase 1
University of Pennsylvania